KYTH-105 Approval Status
KYTH-105 (setipiprant) is an oral prostaglandin D2 (PGD2) receptor antagonist in development for the treatment of androgenetic alopecia (AGA), or male pattern hair loss.
Development Status and FDA Approval Process for KYTH-105
|Sep 22, 2015||Kythera Biopharmaceuticals Submits Investigational New Drug Application for KYTH-105 to Treat Androgenetic Alopecia|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.